E D I T O R I A L
Editorial to "effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology"
Atrial fibrillation (AF) and heart failure (HF) are two cardiovascular epidemics closely inter-linked through a vicious pathophysiological cycle that can be explained by the presence of common risk factors which induce myocardial cellular and extracellular alterations, electrophysiological and neurohormonal changes, leading finally to both HF and AF. Catheter ablation of AF is a well-established treatment option for patients without HF and is indicated in symptomatic paroxysmal, persistent or longstanding persistent AF patients after at least one antiarrhythmic medication has been tried and proven to be ineffective or poorly tolerated. 1 The frequent coexistence of AF and HF has, in recent years, stimulated research on the safety and efficacy of AF catheter ablation in HF patients. class), and freedom from atrial arrhythmias at 12-month follow-up.
The cohort studied consisted of 242 patients (n = 70 [29%] ischemic, n = 172 [71%] non-ischemic) while, regarding the baseline characteristics, patients with non-ischemic cardiomyopathy were younger, more often women and had higher mean LVEF. The study included patients with both preserved and reduced LVEF with a mean LVEF of 45.6% and this is a major difference between this study and the CASTLE-AF as CASTLE-AF enrolled exclusively patients with reduced LVEF. Black-Maier E et al found that all-cause adverse events were similar in the two groups (15% vs 17%, P = .7), while NYHA class and MAFSI scores improved significantly at follow-up in both groups and did not differ according to HF etiology. Furthermore, no significant differences were observed in freedom from recurrent atrial arrhythmias at 12 months between ischemic (74%) and non-ischemic patients (78%).
Despite the limitations of the study by Black-Maier E et al, mainly arising from its retrospective nature, the small sample size and the between group differences in the baseline characteristics, this study provides further important evidence of the safety and efficacy of AF catheter ablation procedure in HF patients, independent of the type of cardiomyopathy. Furthermore, this consists a starting point for future prospective studies with a larger sample size that will elucidate the role of AF catheter ablation in ischemic and non-ischemic cardiomyopathy patients and additionally investigate the role of AF catheter ablation in specific subtypes of non-ischemic cardiomyopathy.
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